T. Do Amaral Miranda

T. Do Amaral Miranda

Auto-generated profile, based on publicly available information

T. Do Amaral Miranda

Division of Medical Oncology, BC Cancer, Vancouver, Canada

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2025 in ESMO Gastrointestinal Oncology
Verified
Journal Article
Open access
RPR.D. Peixoto
R.D. Peixoto
JLJ.M. Loree
J.M. Loree
TMT.A. Miranda
T.A. Miranda
JVJoao Paulo Solar Vasconcelos
Joao Paulo Solar Vasconcelos
DRD.J. Renouf
D.J. Renouf
HLH.J. Lim
H.J. Lim
Colorectal liver metastases (CRLM) pose a significant challenge in oncological care, with surgical resection offering the best chance for long-term survival. Despite curative-intent liver metastasectomy, recurrence rates remain high, underscoring the need for effective adjuvant therapies. While adjuvant chemotherapy (AC) improves disease-free survival (DFS), evidence supporting its overall survival (OS) benefit is limited. This manuscript critically evaluates the role of AC following CRLM resection, with a focus on patient-specific factors influencing treatment outcomes across distinct clinical scenarios. The lack of stratification by molecular biomarkers in prior trials highlights a critical gap in current evidence. Future research should integrate biomarker-driven approaches, leverage circulating tumor DNA (ctDNA) for treatment stratification, and explore novel therapies, including immunotherapies and targeted agents, in both perioperative and adjuvant settings.

31 January 2026 in ESMO Gastrointestinal Oncology
Verified
Journal Article
Open access
RFR. Fedrigo
R. Fedrigo
TMT. Do Amaral Miranda
T. Do Amaral Miranda
RPR. D’ALpino Peioxoto
R. D’ALpino Peioxoto
Sharlene GillSharlene Gill
Sharlene Gill
FBF. Benard
F. Benard
JLJonathan M Loree
Jonathan M Loree
Neuroendocrine neoplasms are uncommon malignancies with variable prognosis. With a growing number of available therapies and recent data supporting earlier initiation of radioligand therapy, we aimed to characterize attrition between lines of therapy to inform treatment sequencing and establish baseline assumptions for future health technology assessments. In this retrospective chart review, patients with metastatic gastroenteropancreatic neuroendocrine tumors (NETs) who received one or more systemic therapies from January 2010 to December 2023 were reviewed. The primary endpoint was attrition between treatment lines. Logistic regression model was used to identify predictors of attrition. Among 234 patients, 65 (28%) had pancreatic NETs (pNETs) and 169 (72%) had extra-pancreatic gastrointestinal NETs (ep-GI-NETs); median age at diagnosis was 65 years. Maximum number of treatment lines was six for pNETs and four for ep-GI-NETs. First-to-second-line attrition rates were 22% [95% confidence interval (CI) 13% to 36%] and 34% (95% CI 25% to 44%) for pNETs and ep-GI-NETs, respectively. Somatostatin analogs were the preferred first line in 194 patients (83%). Peptide receptor radionuclide therapy was administered to 13 pNETs (20%) and 42 ep-GI-NETs (25%). Median first-line progression-free survival (PFS) was 8.8 months and 26.1 months for pNETs and ep-GI-NETs, respectively. Patients treated in the latter cohort (2021-2023) had a lower risk of attrition compared with those in the earlier cohort (2010-2020) (odds ratio 0.38, 95% CI 0.14-0.94, P = 0.046). Despite longer first-line PFS, patients with ep-GI-NETs faced higher attrition rates. These findings emphasize the need to prioritize the most effective therapies early during treatment sequencing to ensure patients are exposed to the most active agents.